Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAL-083 in recurrent glioblastoma (STAR-3)
NCT03149575Phase 3Terminated
- Sponsor
- DelMar Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dianhydrogalactitol in glioblastoma (GBM) and Gliosarcoma (GS) (2 arms), sponsored by DelMar Pharmaceuticals. Primary endpoint: Overall Survival at 12 months. Started Oct 2017; status: terminated.
02
Drugs
dianhydrogalactitol
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT03149575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03149575.